Cross-border M&A is growing increasingly complex. Against a backdrop of heightened regulatory scrutiny, shifting tariff regimes, and widening valuation gaps, dealmakers are under pressure to get the fundamentals right – from strategic alignment to post-deal integration.
To help clients navigate this dealmaking environment, we’ve just launched Dealonomics. This new report, developed in collaboration with Bayes Business School’s M&A Research Centre, is based on analysis of almost 900 cross-border transactions and a global survey of 850 dealmakers.
It provides a comprehensive view of the current M&A landscape and explores the defining characteristics of successful deals, sector and market performance, and the risks that frequently get overlooked.
Explore our Dealonomics findings
Download the full report to explore the trends shaping cross-border M&A and learn what they reveal about the future of dealmaking.
Access now
The Dealonomics podcast
Dealonomics explores the forces shaping global M&A, with market experts joining us to share their views on the latest trends influencing dealmaking.
Listen nowIf you’d like to discuss what our Dealonomics research could mean for you, please get in touch.
Corporate/M&A & capital markets
We know what it takes to execute high-value transactions with confidence. Our expertise spans the full value spectrum, with a particular focus on cross-border M&A. Combining deep market insight with strategic precision, we help clients navigate complex legal, regulatory, and commercial landscapes, ensuring deals are completed seamlessly and successfully.
Learn moreLatest news & insights
Sustainability Stories: Notpla
Rodrigo Garcia and Pierre Paslier, co-founders of Notpla, share how they've harnessed the power of nature to reduce harmful single-use plastics.
by Ian Moore
EU Inc. – The 28th Regime: How the European Commission intends to revolutionise the formation of companies
Investing in the German Audit and Tax Advisory Market – Opportunity Amid Regulatory Debate
by multiple authors
More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies
Advising on Tropic Biosciences' US$105 million Series C financing
by multiple authors